2009-11-02 16:07:54 - Nottingham, UK (November 2 2009) Novozymes Biopharma, part of Novozymes A/S world leader in bioinnovation has claimed the Bronze Innovation Award at the CPhI Worldwide 2009 in Madrid, Spain, for its albumin fusion technology, albufuse®. The CPhI Innovation Awards are designed to reward organizations that play a leading role in delivering groundbreaking innovations within the pharmaceutical industry and the company is delighted to add this accolade to its ever-growing collection of industry awards.

Following its success in 2008, winning the Gold Innovation Award for its novel form of hyaluronic acid, HyaCare®, the company is delighted to have once again been recognized. This year’s awards received a record number of applications, with albufuse in the top six finalists. All six nominees presented their entries to the award’s panel of judges at the show with

Dr. Dave Mead, Business Development Director, Novozymes Biopharma, securing the bronze award with a presentation demonstrating the innovation behind albufuse technology.

Novozymes Biopharma’s albufuse technology provides molecular fusion of albumin to protein drug candidates for improved half-life and bioavailability. The simple, single step expression platform is a natural alternative to other technologies such as PEGylation, a chemical conjugation, offering less frequent administration and reduced dosage. In addition, the technology offers customers the benefits of absolutely consistent products, with more simple production and competitive costs enabling long-term supply in large volume quantities.

The CPhI Innovation Awards are established as the showcase for outstanding work in developing research and technology, setting the standards for the pharmaceutical manufacturing industry. The award’s judging panel took into consideration a number of factors including effective development of the technology and the key benefits it offers to the pharmaceutical industry.

“We are thrilled to have won the bronze award in recognition of our albufuse technology. It is a remarkable achievement as this year’s awards attracted a high standard of entrants,” comments Dr. Dave Mead. “albufuse offers exceptional and clinically proven performance to our customers and has many clinical advantages over existing methods of manufacture.”

For further information on albufuse, please visit www.biopharma.novozymes.com.

About Novozymes
Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow’s industrial biosolutions, improving our customers' business and the use of our planet's resources.

With over 700 products used in 130 countries, Novozymes’ bioinnovations improve industrial performance and safeguard the world’s resources by offering superior and sustainable solutions for tomorrow’s ever-changing marketplace.

Novozymes’ natural solutions enhance and promote everything from removing trans fats in cooking, to advancing biofuels to power the world tomorrow. Our never-ending exploration of nature’s potential is evidenced by over 6,000 patents, showing what is possible when nature and technology join forces.

Our 5,000+ employees working in research, production and sales around the world are committed to shaping business today and our world tomorrow.

Contacts:
Novozymes Biopharma:
Sally Vernon, Marketing Communications Manager
SYKE@novozymes.com
Tel. +44 115 955 3355

Corporate Contacts:
Press and media:
Johan Melchior
Tel. (direct): +45 4446 0690
Tel. (mobile): +45 3077 0690
René Tronborg
Tel. (direct): +45 4446 2274
Tel. (mobile): +45 3077 2274
Paige Donnelly (USA)
Tel. (direct): +1 919 494 3209
Tel. (mobile): +1 919 218 4501

Investor relations:
Tobias Bjørklund (USA)
Tel. (direct): +1 919 494 3483
Tel. (mobile): +1 919 649 2565